The optimal timing for non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents

International Journal of Cardiology

Volumn 139, Issue 3, 2010, Pages 313-316

  Choi, Cheol Ung ^a   Rha, Seung Woon ^a   Jin, Zhe ^a   Chen, Kang Yin ^a   Minami, Yoshiyasu ^a   Kim, Ji Hoon ^a   Na, Jin Oh ^a   Suh, Soon Yong ^b   Kim, Jin Won ^a   Kim, Eung Ju ^a   Park, Chang Gyu ^a   Seo, Hong Seog ^a   Oh, Dong Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Drug eluting stent; Non cardiac surgery; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATINE KINASE; TROPONIN T; ZOTAROLIMUS;

ADVERSE OUTCOME; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; Q WAVE; COMPARATIVE STUDY; ELECTIVE SURGERY; LETTER; METHODOLOGY; MIDDLE AGED; STANDARD; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS;

EID: 80052540267     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.10.050     Document Type: Article

References (15)

1. Wilson SH, Fasseas P, Orford JL, Lennon RJ, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003;42:234-40.
2. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005;95:755-7.
3. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
4. Guagliumi G, Farb A, Musumeci G, et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1.
5. Grube E, Silber S, Hauptmann KE, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 2005;96:79-82.
6. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
7. Satler LF. Recommendations regarding stent selection in relation to the timing of noncardiac surgery postpercutaneous coronary intervention. Catheter Cardiovasc Interv 2004;63:146-7.
8. Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001;52:333-6.
9. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 2004;17:21-7.
10. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-6.
11. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
12. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
13. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
14. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
15. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131: 149-50.